SOURCE: VIVALIS

November 06, 2007 11:46 ET

VIVALIS : PORTZAMPARC INVESTMENT FIRM INITIATES VIVALIS COVERAGE WITH A PRICE TARGET OF €11

NANTES, FRANCE--(Marketwire - November 6, 2007) - VIVALIS (Euronext Paris: VLS), announces today the initiation of a coverage by the independent investment firm PORTZAMPARC, with a "BUY" recommendation and a price target of EUR 11.

VIVALIS is already covered since its listing on Euronext in June 2007 by NATIXIS SECURITIES analysts. This new coverage initiated by PORTZAMPARC will contribute to strengthen the company's visibility.

FRANCK GRIMAUD, VIVALIS CEO declared: "VIVALIS is pleased to announce this new coverage by PORTZAMPARC. It confirms the strong interest that the company is meeting since its listing on Eurolist Paris in June. We are willing to increase the number of analysts following VIVALIS business and developments. From that perspective, this second coverage is a very positive and promising step".

*******************

Next calendar:

February 15th, 2008 after Euronext closing: Year 2007 Revenues

*******************

About VIVALIS (www.vivalis.com)

VIVALIS (Euronext: VLS) is a biopharmaceutical company specialised in vaccines and in viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants research & commercial licences to its proprietary Ebx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.

- Recombinant therapeutic protein and monoclonal antibody production systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary Ebx® embryonic stem cell lines to manufacture recombinant therapeutic proteins.

- The build-up of a proprietary portfolio of vaccines and anti- viral molecules.

Based in Nantes (France), VIVALIS was created in 1999 by Group GRIMAUD (1350 employees), the n degrees2 group worldwide in avian genetic breeding. VIVALIS has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

Eurolist Paris - Sector B - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

Investors Relation :

VIVALIS

Franck Grimaud, C.E.O

Email : investors@vivalis.com

NEWCAP

Financial Communication Agency

Steve Grobet / Emmanuel Huynh

Tel. : +33 (0) 1 44 71 94 91

Email : vivalis@newcap.fr

About PORTZAMPARC (www.portzamparc.fr)

PORTZAMPARC is an Investment firm specialized in midcaps. It offers a large range of financial and advisory services: Initial Public Offerings, Bonds issues, Delisting of shares, Liquidity contracts,Corporate broking

Contact:

Arnaud Guérin

Analyste Financier

Email : guerin@portzamparc.fr

This information is provided by CompanynewsGroup

Contact Information